In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme "LP-GP Ecosystem Synergy: Coordinating Policy, Capital, and Innovation."

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration, Standing as "Back-to-Back Comrades" for Entrepreneurs

Image: Event Scene

01
[Roundtable Moment]
More Than Just Capital: "Back-to-Back Comrades"

At the roundtable forum held at noon, Zhu Pai shared the stage with guests from Deloitte, Guangzhou Guochuang Investment, Songhe Capital, and Legend Capital to explore the deep integration of capital and innovation amid industrial cycles.

Image: Roundtable Forum – "LP-GP Ecosystem Synergy: Coordinating Policy, Capital, and Innovation"

Addressing the topic of "synergy" at the roundtable, Efung Capital expressed: In the current period where the biomedical industry oscillates between winter chill and spring warmth, the relationship between investors and entrepreneurs is no longer a simple "question and answer" dynamic, but rather that of "back-to-back comrades." True synergy lies in capital's reverence for the laws of scientific research, the entrepreneur's commitment to clinical value, and the shared journey of navigating policy currents to find the narrow path toward commercial success.

Image: Mr. Zhu Pai, CEO of Efung Capital

During the roundtable discussion, Zhu Pai's insights resonated strongly with the audience. He emphasized that the role of capital should extend beyond financial support to becoming the most trusted long-term companion for entrepreneurs, helping them navigate complex and ever-changing environments to collectively transcend market cycles and achieve value realization.

02
[BIONIGHT Reception]
Toasting to Innovation, Moving Forward Together

Intellectual exchanges were not confined to the forum but continued into the evening reception. At the gathering, over a hundred leaders from industrial groups, executives of listed companies, and founders of innovative enterprises raised their glasses in celebration, engaging in conversations that extended beyond business to forge shared convictions and a collective vision for the industry's future.

As a dedicated player in the biomedical sector, Efung Capital firmly believes that innovation-driven drug development is a marathon—requiring not only rational strategic resolve but also heartfelt mutual support. This sincerity and warmth represent the most precious driving force on China's biomedical journey ahead. Moving forward, we will continue to use capital as our oar and innovation as our sail, joining hands with more industry partners to navigate toward a brighter future for China's biomedical industry.